Research: therapy for chronic hepatitis C

Therapy AbbVie shows 96% sustained virologic response (SVR12) in Phase III trials in previously treated patients with hepatitis C genotype first

Published data confirm the results of Phase II clinical trials c comparable virologic response and tolerability
SAPPHIRE-II – the second of the six studies phase III, studying triple (3D) regimen
Expected new information on clinical trials AbbVie, studying 3D mode in combination with ribavirin and without it, including on the treatment of hepatitis C in patients with cirrhosis
NORTH CHICAGO, ILLINOIS , December 10, 2013 – AbbVie (NYSE: ABBV) published the results of a Phase III clinical studies investigating the triple (3D) mode antiviral therapy with direct action in combination with ribavirin in patients with chronic hepatitis C genotype first (GT1) . The study SAPPHIRE-II sustained virologic response at the end of the 12th week of treatment (SVR12) was achieved in 96% of 394 patients who previously did not report on the clinical success of therapy with pegylated interferon and ribavirin , including about 49% of those who have completely missed the answer a previous therapy. The majority of patients were genotype 1a , which is considered the most difficult to treat hepatitis C virus subtype rate of sustained virologic response (SVR12) in patients with genotype 1a and 1b was 96 % and 97 %, respectively. Virological relapse or breakthrough occurred in 2% of patients treated with 3D mode in combination with ribavirin . Moreover, the frequency of treatment interruption due to side effects was 1%. Continue reading